General Information of Drug (ID: DMU4BL2)

Drug Name
PMID24900428C14 Drug Info
Synonyms GTPL8154; BDBM50400754
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
71461150
TTD Drug ID
DMU4BL2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [2]
US9096594, 3 DM8UOKE N. A. N. A. Patented [3]
IC261 DMXB95R Pancreatic cancer 2C10 Preclinical [4]
D-4476 DMHD3R8 Chronic lymphocytic leukaemia 2A82.0 Preclinical [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
IC261 DMXB95R Pancreatic cancer 2C10 Preclinical [4]
D-4476 DMHD3R8 Chronic lymphocytic leukaemia 2A82.0 Preclinical [6]
PF-4800567 DM8P9ST Chronic lymphocytic leukaemia 2A82.0 Preclinical [7]
PF-670462 DMTJBP9 Chronic lymphocytic leukaemia 2A82.0 Preclinical [8]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase I alpha (CSNK1A1) TTFQEMX KC1A_HUMAN Inhibitor [1]
Casein kinase I delta (CSNK1D) TTH30UI KC1D_HUMAN Inhibitor [1]
Casein kinase I gamma-2 (CSNK1G2) TT0UZJ9 KC1G2_HUMAN Inhibitor [1]

References

1 Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
2 Clinical pipeline report, company report or official report of BioTheryX.
3 Kinase inhibitors and methods of use thereof. US9096594.
4 Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
5 Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8.
6 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
7 Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
8 Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.